Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors
2024

Methylation Profiling of Pituitary Tumors

Sample size: 64 publication 10 minutes Evidence: high

Author Information

Author(s): Jotanovic Jelena, Boldt Henning Bünsow, Burton Mark, Andersen Marianne Skovsager, Bengtsson Daniel, Bontell Thomas Olsson, Ekman Bertil, Engström Britt Edén, Feldt-Rasmussen Ulla, Heck Ansgar, Jakovcevic Antonia, Jørgensen Jens Otto L., Kraljevic Ivana, Kunicki Jacek, Lindsay John R., Losa Marco, Loughrey Paul Benjamin, Maiter Dominique, Maksymowicz Maria, Manojlovic-Gacic Emilija, Pahnke Jens, Petersenn Stephan, Petersson Maria, Popovic Vera, Ragnarsson Oskar, Rasmussen Åse Krogh, Reisz Zita, Saeger Wolfgang, Schalin-Jäntti Camilla, Scheie David, Terreni Maria Rosa, Tynninen Olli, Whitelaw Ben, Burman Pia

Primary Institution: Uppsala University, Uppsala, Sweden

Hypothesis

Can genome-wide methylation analysis differentiate between aggressive and benign pituitary neuroendocrine tumors?

Conclusion

The study found distinct methylation and copy-number variation profiles that separate aggressive and metastatic pituitary tumors from benign ones.

Supporting Evidence

  • Aggressive and metastatic pituitary tumors showed distinct DNA methylation patterns compared to benign tumors.
  • The study included a large international cohort of 64 patients.
  • Copy-number variations were more frequent in aggressive and metastatic tumors.
  • The findings may help in identifying patients at risk for aggressive pituitary tumors.
  • Methylation analysis could refine follow-up routines and treatment strategies.

Takeaway

Scientists looked at the DNA of pituitary tumors to see if they could tell which ones were dangerous and which ones were not. They found that the dangerous ones had different patterns in their DNA.

Methodology

Genome-wide methylation analysis and copy-number variation calculations were performed on tumor tissue from 64 patients.

Limitations

The study did not include lactotroph tumors in the benign cohort and lacked genetic analyses to explore associations between genetic and epigenetic events.

Participant Demographics

The cohort included 64 patients (39 males) with aggressive (48) and metastatic (16) pituitary tumors.

Statistical Information

P-Value

1.3×10–7

Statistical Significance

p<1.3×10–7

Digital Object Identifier (DOI)

10.1007/s00401-024-02836-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication